Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
Wall Street Week Ahead
07:07am, Sunday, 02'nd Nov 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
AstraZeneca to face questions on Trump MFN deal, patent expiries and pipeline
11:39am, Friday, 31'st Oct 2025
When AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) reports third-quarter results next Thursday, 6 November, with investors and analysts will be keen to hear about the financial implications of the 'most fa
Short Interest in AstraZeneca PLC ADRhedged (BATS:AZNH) Increases By 200.0%
01:48am, Friday, 31'st Oct 2025
AstraZeneca PLC ADRhedged (BATS: AZNH - Get Free Report) was the target of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 300 sha
FTSE Index shares to watch next week: BT, BP, IAG, AstraZeneca, Marks & Spencer
01:19am, Friday, 31'st Oct 2025
The FTSE 100 Index has been in a strong bull run this year and is now trading at a record high of £9,760. It has jumped by 30% from its lowest point this year.
AstraZeneca PLC $AZN Stock Holdings Increased by Sumitomo Mitsui Trust Group Inc.
04:53am, Thursday, 30'th Oct 2025
Sumitomo Mitsui Trust Group Inc. lifted its stake in AstraZeneca PLC (NASDAQ: AZN) by 15.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (
AstraZeneca PLC ADRhedged (BATS:AZNH) Short Interest Up 200.0% in October
01:58am, Thursday, 30'th Oct 2025
AstraZeneca PLC ADRhedged (BATS: AZNH - Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 30
Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors
07:16pm, Tuesday, 28'th Oct 2025
Astrazeneca (AZN) closed at $82.61 in the latest trading session, marking a -1.72% move from the prior day.
Pipeline power keeps AstraZeneca in rude health
06:53am, Monday, 27'th Oct 2025
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) is looking more marathon runner than sprinter these days. The pharmaceuticals giant has spent years building a pipeline that looked sprawling and costly.
AstraZeneca found in breach of industry code over Symbicort marketing, industry body says
04:51am, Friday, 24'th Oct 2025
AstraZeneca breached the UK pharmaceutical industry's code of practice by using a claim that misleadingly implied its Symbicort asthma drug was suitable for all newly diagnosed patients aged 12 years
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
10:50am, Monday, 20'th Oct 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca hails major breakthroughs with breast-cancer drugs
06:53am, Monday, 20'th Oct 2025
An executive at AstraZeneca says breast-cancer drugs that the company highlighted at an industry conference over the weekend could represent $10 billion worth of company sales in five years' time.
AstraZeneca's Datroway extends survival in aggressive breast cancer
02:32am, Sunday, 19'th Oct 2025
AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat for
AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment
10:33am, Saturday, 18'th Oct 2025
AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.
AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash
10:30am, Saturday, 18'th Oct 2025
AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO.
TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps
04:17pm, Friday, 17'th Oct 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen's TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years
